Zimmer Biomet (NYSE:ZBH) Releases FY 2025 Earnings Guidance

Zimmer Biomet (NYSE:ZBH) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 8.150-8.350 for the period, compared to the consensus EPS estimate of 8.550. The company issued revenue guidance of $7.8 billion-$7.9 billion, compared to the consensus revenue estimate of $8.0 billion.

Zimmer Biomet Stock Down 1.2 %

Shares of ZBH traded down $1.24 during midday trading on Friday, hitting $101.45. The company had a trading volume of 1,302,677 shares, compared to its average volume of 1,777,397. The stock has a market cap of $20.20 billion, a price-to-earnings ratio of 19.27, a PEG ratio of 1.88 and a beta of 1.02. The company’s 50 day moving average price is $107.56 and its 200 day moving average price is $108.16. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet has a 52 week low of $100.67 and a 52 week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. During the same quarter in the prior year, the firm posted $2.20 EPS. On average, equities research analysts predict that Zimmer Biomet will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were issued a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.95%. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Barclays dropped their price target on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research report on Thursday, December 12th. Stifel Nicolaus raised their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Raymond James lowered their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Friday. Finally, Wells Fargo & Company upped their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $124.70.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.